ClinicalTrials.gg
CompletedNCT00948142Updated Apr 19, 2019

Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections

A Phase 2 interventional study of CEM-102 and Linezolid in Skin Diseases, Bacterial, sponsored by Arrevus Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-19.

Sponsored by Arrevus Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies in Skin Diseases, Bacterial with a site in United States — 1 open to participants now, 2 under way, 1 of them phase 3. Skin Diseases, Bacterial · United States.

Enrollment
13th of 21
198 · median 234
Started
2009
the only one that year
Phase 2
9 of 22
none open now
Registered
9th of 22
by date
Lead sponsor
1 of 22
Arrevus Inc.

Among the 22 studies in Skin Diseases, Bacterial with a site in United States, this one is the 13th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2009, is one of 9 in phase 2, and was the 9th registered.

Skin Diseases, Bacterial

37 studies on the registry are indexed under Skin Diseases, Bacterial; 2 are open to participants now.

Browse Skin Diseases, Bacterial studies →

Open to participants now

1 of the 22 studies in Skin Diseases, Bacterial with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1 Skin Diseases, Bacterial study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Skin Diseases, Bacterial with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of CEM-102 compared to Linezolid in the treatment of acute bacterial skin structure infections (ABSSIs).

Read the detailed description

ABSSIs are common and affect all age groups. In recent years, ABSSIs caused by multi-drug resistant pathogens, especially methicillin-resistant Staphylococcus aureus (MRSA) have become more common. There is an urgent need for additional antibacterial drugs with modes of action different from those currently available. CEM-102 is one such agent with excellent activity against S. aureus, including MRSA.

03

Conditions studied

  • Skin Diseases, Bacterial

Keywords

  • Acute Bacterial Skin and Skin Struction Infections; Bacterial Skin Diseases; Staphylococcal Skin Infections; MRSA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of acute bacterial skin-structure infection (ABSSI) of no more than 7 days duration which was suspected or proven to be caused, at least in part, by a gram-positive pathogen.
  • Eligible infections included cellulitis measuring at least 10 cm length and width or 100 cm squared, with or without a focal abscess, and surgical or traumatic wound infections
  • Infection which in the opinion of the investigator will require 10-14 days of antibacterial therapy.
  • Have at least 3 of the following local and/or systemic symptoms and/or signs of infection: purulent or seropurulent drainage/discharge, erythema, fluctuance, heat/localized warmth, pain/tenderness to palpation, swelling/induration, regional lymph node swelling or tenderness, temperature >=100.4 degree F, increased white blood cell count, or bandemia.
  • Must not have received treatment with another systemic antibiotic for the current ABSSI.

Exclusion criteria

Exclusion Criteria:

  • Superficial skin structure infections such as folliculitis, carbuncles, furunculosis, cutaneous abscesses, and simple cellulitis.
  • Infections involving burns, human or animal bites, or chronic diabetic foot ulcers.
  • Suspected polymicrobial infection involving Pseudomonas aeruginosa
  • Anticipated need for >14 days of antibiotic therapy.
  • Infections complicated by the presence of prosthetic materials that will not be removed, such as permanent cardiac pacemaker battery packs, mesh, or joint replacement prosthesis.
  • Known significant renal, hepatic, or hematologic impairment.
  • Received prior potentially effective antimicrobial therapy for the acute bacterial skin and skin structure infection, unless they were failing therapy after 48 hours or had a gram-positive pathogen non-susceptible to prior therapy identified as a causative pathogen.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
198 participants (actual)

Study arms

  • Active comparator
    Linezolid

    600 mg BID

    Drug: Linezolid

  • Experimental
    CEM-102 Regimen A

    Drug: CEM-102

  • Experimental
    CEM-102 Regimen B

    Drug: CEM-102

Interventions

  • 600 mg BID oral tablets for 10-14 days

    Also known as: fusidic acid

  • 600 mg BID oral tablets

    Also known as: Zyvox

  • 1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days

    Also known as: fusidic acid

06

What researchers measure

Primary outcomes

  1. Clinical Success at Test of Cure (TOC) for the intent-to-treat (ITT) population

    Meets the following definition for clinical success: continued complete resolution of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required

    Time frame: 7 to 14 days after the last dose of study drug

  2. Clinical Success at Test of Cure (TOC) for the clinically evaluable (CE) population

    Meets the following definition for clinical success: continued complete resolution of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required

    Time frame: 7 to 14 days after the last dose of study drug

Secondary outcomes

  1. Clinical Success at end of treatment (EOT) for the intent-to-treat (ITT) population

    Meets the following definition for clinical success: Complete resolution of the signs and symptoms of the ABSSI and no further study drug therapy is required.

    Time frame: 10-14 days of study drug

  2. Clinical Success at the test of cure (TOC) in the microbiological intent-to-treat (MITT) and population

    Meets the following definition for clinical success: Complete resolution of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required.

    Time frame: 7 to 14 days after the last dose of study drug

  3. Clinical Success at the end of treatment (EOT) for the Clinically evaluable (CE) population

    Meets the following definition for clinical success: complete resolution of the signs and symptoms of the ABSSI and no further study drug therapy is required.

    Time frame: 10-14 days of study drug

  4. Clinical success at the end of treatment (EOT) for the microbiological intent-to-treat (MITT) population

    Meets the following definition for clinical success at the end of treatment: complete resolutoin of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required

    Time frame: 10-14 days of study drug

  5. Clinical Success at end of treatment (EOT) for the microbiologically evaluable (ME) population

    Meets the following definition for clinical success: complete resolution of signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required.

    Time frame: 10-14 days of study drug

  6. Clinical Success at test of cure (TOC) for the microbiologically evaluable (ME) population

    Meets the following definition of clinical success: continued complete resolution of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required.

    Time frame: 7-14 days after the last dose of study drug

  7. Clinical success at the test of cure (TOC) by baseline pathogen for the microbiological intent-to-treat (MITT) population

    Meets the following definition for clinical success: continued complete resolution of the signs and symptoms of the ABSSI and no additonal systemic antibacterial therapy is required

    Time frame: 7-14 days after the last dose of study drug

  8. Clinical success at test of cure (TOC) by baseline pathogen for the microbiologically evaluable (ME) population

    Meets the following definition for clinical success: continued complete resolution of the signs and symptoms of the ABSSI and no additional systemic antibacterial therapy is required

    Time frame: 7 to 14 days after the last dose of study drug

  9. By-pathogen microbiological success at test of cure (TOC) for the microbiological intent-to-treat (MITT) population

    Successful responses included: eradication: the basline causative pathogen was absent from the culture(s) presumed eradication: the patient's clincial response was success, and no culture available.

    Time frame: 7-14 days after the last dose of study drug

  10. By-pathogen microbiological success at test of cure (TOC) for the microbiologically evaluable (ME) population

    Successful responses included: eradication: the basline causative pathogen was absent from the culture(s) presumed eradication: the patient's clincial response was success, and no culture available.

    Time frame: 7-14 days after the last dose of study drug

  11. By-patient microbiological success at test of cure (TOC) for the microbiological intent-to-treat (MITT) population

    Successful responses included: eradication: the baseline causative organisms have a response of eradication. presumed eradication: all baseline causative organism(s) have a response of presumed eradication combined eradication/presumed eradication: in cases where baseline causative organisms were from a blood and an ABSSI culture

    Time frame: 7-14 days after the last dose of study drug

  12. By-patient microbiological success at test of cure (TOC) for the microbiologically evaluable (ME) population

    Successful responses included: eradication: the baseline causative organisms have a response of eradication. presumed eradication: all baseline causative organism(s) have a response of presumed eradication combined eradication/presumed eradication: in cases where baseline causative organisms were from a blood and an ABSSI culture

    Time frame: 7-14 days after the last dose of study drug

07

Study locations

16 sites
  • Chula Vista, California 91911, United States
  • La Mesa, California 91942, United States
  • Los Angeles, California 90015, United States
  • Oceanside, California 92056, United States
  • Oxnard, California 93030, United States
  • Pasadena, California 91105, United States
  • Santa Ana, California 92701, United States
  • Torrance, California 90501, United States
  • Torrance, California 90509, United States
  • Columbus, Georgia 31904, United States
  • Savannah, Georgia 31406, United States
  • Springfield, Illinois 62701, United States
  • Detroit, Michigan 48202, United States
  • Butte, Montana 59701, United States
  • Somers Point, New Jersey 08244, United States
  • Akron, Ohio 44304, United States
08

References and documents

Publications

  • Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Das A, Fernandes P. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis. 2011 Jun;52 Suppl 7:S520-6. doi: 10.1093/cid/cir167. PubMed 21546629 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2009
First posted
Jul 29, 2009
Start
Aug 2009
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results delay requested
Feb 23, 2011
Last update
Apr 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00948142
Lead sponsor
Arrevus Inc.
Responsible party
Sponsor
First posted
Jul 29, 2009
Start date
Aug 2009
Primary completion
Mar 2010
Completion
Mar 2010
Last update
Apr 19, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fusidic Acid

Start the discussion